文献速递头颈外科鼻科

程序性死亡配体1在鼻腔鼻窦癌中的表达及免疫治疗靶点价值

Programmed death ligand-1 expression as immunotherapeutic target in sinonasal cancer.
PubMed 文献 · Head Neck · 2018-01-22

该研究评估了53例鼻腔鼻窦鳞状细胞癌(SCC)和126例肠型腺癌(ITAC)样本中程序性死亡配体1(PD-L1)的表达,并将其与临床病理特征及随访数据关联。结果显示,肿瘤细胞膜性PD-L1阳性率在SCC中为34%(18/53),在ITAC中为17%(22/126);浸润免疫细胞PD-L1阳性率分别为45%(24/53)和33%(41/126)。PD-L1表达与临床病理参数无关,也不是独立的生存风险因素,但部分鼻腔鼻窦SCC和ITAC患者可能从免疫检查点抑制剂治疗中获益。

要点

  • 鼻腔鼻窦SCC肿瘤细胞PD-L1阳性率为34%,ITAC为17%。
  • PD-L1表达与临床病理参数无关,非独立生存风险因素。
  • 部分鼻腔鼻窦SCC和ITAC患者可能从免疫检查点抑制剂治疗中获益。

核心结论

  • PD-L1阳性似乎不具有预后价值,但部分鼻腔鼻窦SCC和ITAC患者可能从免疫检查点抑制剂治疗中获益。

研究设计与样本

  • 研究评估了53例鼻腔鼻窦鳞状细胞癌(SCC)和126例肠型腺癌(ITAC)样本中PD-L1的表达,并与临床病理特征及随访数据关联。

主要发现

  • 肿瘤细胞膜性PD-L1染色阳性在鼻腔鼻窦SCC样本中占34%(18/53),在ITAC样本中占17%(22/126)。
  • 浸润免疫细胞PD-L1阳性在鼻腔鼻窦SCC样本中占45%(24/53),在ITAC样本中占33%(41/126)。
  • PD-L1表达与临床病理参数无相关性,且不是独立的生存风险因素。

临床怎么用

  • PD-L1表达检测可能有助于识别适合免疫检查点抑制剂治疗的鼻腔鼻窦SCC和ITAC患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sinonasal cancer carries a poor prognosis, especially in recurrent stages, and it is a disease with very limited treatment options. METHODS: The expression of programmed death ligand-1 (PD-L1) as a marker for immunotherapy was evaluated in 53 sinonasal squamous cell carcinoma (SCC) and 126 intestinal-type adenocarcinoma (ITAC) samples. Results were correlated to clinicopathological characteristics and follow-up data. RESULTS: Membranous PD-L1 staining of tumor cells was observed in 34% (18/53) of the sinonasal SCC samples and in 17% (22/126) of the ITAC samples. The PD-L1 positivity on infiltrating immune cells occurred in 45% (24/53) of the sinonasal SCC samples and in 33% (41/126) of the ITAC samples. Expression of PD-L1 showed no correlation to clinicopathological parameters and was not an independent risk factor for survival. CONCLUSION: The PD-L1 positivity does not seem to have prognostic value. However, a proportion of patients with sinonasal SCC and ITAC may benefit from therapy with immune checkpoint inhibitors that recently have been approved for clinical application in head and neck cancer.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Riobello C, Vivanco B, Reda S, et al. Programmed death ligand-1 expression as immunotherapeutic target in sinonasal cancer. Head Neck. 2018. PMID: 29356178. doi:10.1002/hed.25067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。